Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report
Open Access
- 9 July 2024
- journal article
- research article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (6) , 102185
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 UpdateEndocrine Practice, 2023
- The GLP‐1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetesClinical Endocrinology, 2023
- Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trialExpert Opinion on Drug Metabolism & Toxicology, 2021
- Thyroid dysfunction prevalence and relation to glycemic control in patients with type 2 diabetes mellitusDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019
- Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine MetabolismThyroid®, 2018
- Incidence and prevalence of thyroid dysfunction in type 1 diabetesJournal of Diabetes and its Complications, 2016
- A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid CancerExperimental Diabetes Research, 2012
- Effect of weight loss after gastric bypass surgery on thyroid function in euthyroid people with morbid obesityClinical Obesity, 2012
- The interface between thyroid and diabetes mellitusClinical Endocrinology, 2011
- Weight Loss Through Gastric Banding: Effects on TSH and Thyroid Hormones in Obese Subjects With Normal Thyroid FunctionObesity, 2010